Why the study?
Does the GPIIb/IIIa antagonist MK-852 alter the expression of P-selectin, tissue factor, and CD40 ligand on platelet-leucocyte conjugates?
Does the GPIIb/IIIa antagonist MK-852 alter the expression of P-selectin, tissue factor, and CD40 ligand on platelet-leucocyte conjugates?
GPIIb/IIIa antagonists promote the formation of pro-inflammatory and pro-thrombotic platelet-leucocyte conjugates, which may explain some of the negative clinical effects associated with their use.
Answers are grounded in this paper and cite their sources.
May underlie GPIIb/IIIa antagonist harms; leaves open human relevance from this animal study.
This study was to investigate the appearance of P-selectin, tissue factor (TF) and CD40 ligand (CD40L) on platelet-leucocyte conjugates in the absence and presence of a GPIIb/IIIa antagonist, MK-852, and the effect of adding EDTA to pre-formed conjugates. The purpose was to find out whether these antigens are displaced from the conjugates along with the platelets, thus providing information on their location. Hirudinized blood was stirred with collagen ((2 microg/mL) in the absence and presence of MK-852 (10 micromol/mL)). P-selectin, TF and CD40L were measured on platelet-leucocyte conjugates (CD42a positive monocytes and neutrophils) and on single platelets by flow cytometry. Measurements were also made after subsequent addition of EDTA (4 mmol/L). Platelet-leucocyte conjugate formation was markedly enhanced in the presence of MK-852. P-selectin, TF and CD40L expression on the conjugates was also enhanced. Monocytes bound more platelets and expressed more P-selectin, TF and CD40L than neutrophils. EDTA displaced the majority of platelets from the conjugates and also the P-selectin, TF and CD40L, whereas it did not displaced P-selectin or CD40 ligand from the platelets themselves. It is concluded that a GPIIb/IIIa antagonist promotes formation of platelet-leucocyte conjugates, which display P-selectin, TF and CD40L that appears to be associated with the adherent platelets. Platelet-monocyte conjugates are prime candidates for arterial inflammation and thrombosis. Pro-inflammatory and pro-thrombotic effects of CD40L and tissue factor may be an explanation of the negative clinical effects using GPIIb/IIIa antagonists.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: